CI

At a glance

ClinicalIndex Comparison Record
Phase 3Active· 79 enrolled
Drug / intervention
Placebo Administration +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04810091
NCT04810091Phase 3Active

TELEHEART: Telotristat Ethyl in a Heart Biomarker Study

M.D. Anderson Cancer Center·interventional·Posted Mar 22, 2021·Updated Mar 9, 2026

In Brief

A Phase 3 clinical trial evaluating Placebo Administration, Questionnaire Administration, and 1 other intervention for Locally Advanced Neuroendocrine Neoplasm and Metastatic Neuroendocrine Neoplasm. Active but no longer recruiting, targeting 79 participants across 1 site.

Detailed Summary

This phase III trial compares the effect of telotristat ethyl and the current standard of care somatostatin analog therapy or somatostatin analog therapy alone in treating patients with neuroendocrine tumor that has spread to other places in the body (metastatic). Telotristat ethyl and somatostatin analog therapy may help to control carcinoid syndrome and carcinoid heart disease.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 3Active
20222023202420252026
First PostedMar 22, 2021
Enrollment StartMay 18, 2021
Primary CompletionAug 31, 2025
Study CompletionAug 3, 2026
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 5.3 years ago

Interventions

Placebo Administrationdrug

Given PO

Questionnaire Administrationother

Ancillary studies

Telotristat Ethyldrug

Given PO